SoftOx Solutions 2021-2022

[XCR]

Ble en minifomo. Blir rått når det kommer news.

[Codex87]

Herre sverre nå satt jeg morrakaffen i halsen her Som nevnt ovenfor: det skal lite positive triggere til før det blir en ny fomo-tsunami nå tenker jeg (insert rocket emoji-multiples)

[XCR]

Gratulerer med dagen!

[XCR]

HASJØ HOLDING AS ute av lista.

[Mrodseth]

Stort behov for alternativer til antibiotika.
“Antibiotics Can Lead to Life-Threatening Fungal Infection Because of Disruption to the Gut’s Immune System” https://scitechdaily.com/antibiotics-can-lead-to-life-threatening-fungal-infection-because-of-disruption-to-the-guts-immune-system/

[pips]

Effect of Stabilized Hypochlorous Acid on Re-epithelialization and Bacterial...

[Melhus79]

[TekBot]

SoftOx Solutions AS: to attend and host an educational symposium at the European Wound Management Association Conference

SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical and medical technology company based in Norway, announces that it will attend and host an educational symposium at the European Wound Management Association (EWMA) Conference in Paris, France, from 23-25 May 2022.

The European Wound Management Association (EWMA) is a European not-for-profit umbrella organisation, linking national wound management organisations, individuals and groups with interest in wound care. EWMA was established in 1991 as a charity organisation registered in the UK.
…

Vis børsmeldingen

The EWMA is focused on supporting the implementation of interdisciplinary and cost effective wound care of high quality. EWMA works to reach its objectives by being an educational resource, organising conferences, contributing to international projects related to wound management, actively supporting the implementation of existing knowledge within wound management, and providing information on all aspects of wound management.

SoftOx will be hosting a symposium titled ‘Future practical solutions for fighting antimicrobial resistance in wound care’, which will take place on Wednesday, 25 May 2022, from 12.15-13.15 CEST.

“Microbial resistance is one of the most major threats to human health. Navigating this challenging field of research, we are excited to host a symposium homing in on how we manage antimicrobial resistance in wound care and, importantly, promising and cutting-edge research,” said Geir Almås, CEO SoftOx Solutions AS.

At the Joint EWMA & Journées Cicatrisations Conference, SoftOx will be an exhibitor and presenter. The SWIS-02 study has been selected for oral presentation by its principal investigator, and CEO Geir Almås will present on the EXCITE International approach and participate in a meet-the-experts session as an EXCITE International advisory council member.

Symposium details:
Title: Future practical solutions for fighting antimicrobial resistance in wound care
Date and time: Wednesday, 25 May 2022, 12:15 - 13:15 hrs

Speakers and agenda:

• Prof. Niels Frimodt-Møller (Rigshospitalet, Dept. of Clinical Microbiology, Copenhagen, DK)
Antimicrobial resistance in your practice: an ever more powerful adversary
• Prof. Thomas Bjarnsholt (Copenhagen University Hospital, Dept. of Clinical Microbiology, Copenhagen, DK)
Countering antimicrobial resistance: its history and mechanism of action
• Dr. Klaus Kirketerp-Møller (Wound Healing Center, Bispebjerg University Hospital, Copenhagen, DK)
Fighting antimicrobial resistance in wound care tomorrow: clinical research today

Chair: Geir Almås, CEO SoftOx Solutions AS

A recording of the symposium will be made available on the Company’s website at Investor Presentations - Soft Ox Solutions.

For further information, visit the EWMA conference website here: EWMA 2022 conference - ewma.org

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian biotech/medtech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses.
For more information on SoftOx, visit www.soft-ox.com

Kilde

[XCR]

Liker denne godt. Skikkelig interessevekker og fin plass for å knytte bånd til industrien.

[Mrodseth]

Ikke mangen dager igjen.
Her kan softox snakke opp produktet sitt rett til målgruppen. “nurses, doctors and other healthcare professionals working within wound care. Every year, all these people are brought together at the annual EWMA Conference”. Økt oppmerksomhet er veldigt bra nå mtp partnere, BP og hele det internasjonale forskningsmiljøet.

[rockybalboa]

Yihaa! UNZT UNZT

[Hpbjorn]

Let’s go!

[TekBot]

SOFTOX SOLUTIONS AS: ANNOUNCES POSITIVE PHASE 1 RESULTS FOR SOFTOX INHALATION SOLUTION (SIS)

OSLO – May 19, 2022: SoftOx Solutions AS ("SoftOx” or the “Company”), a clinical-stage pharmaceutical and medtech company based in Norway, today announced top line results from its Phase 1 study evaluating SoftOx Inhalation Solution (SIS). SIS is a novel aqueous formulation of hypochlorous acid (HOCl), a biological oxidant with broad spectrum antimicrobial (antiviral and antibacterial) properties.

In this Phase 1, first-in-human study, nebulised SIS achieved the primary objective of safety and tolerability in healthy subjects. There were no observed local tolerability issues, no adverse effects on pulmonary function, and no serious adverse events.
…

Vis børsmeldingen

“We are highly encouraged by these Phase 1 results demonstrating an acceptable safety and tolerability profile for a potential future inhaled antiviral treatment”, says Dr Christopher Burton, Chief Medical Officer for SIS. “This study paves the way forward for the future clinical development of SIS within infectious disease indications in the upper and lower respiratory tract.”

SIS-01 is a first-in-human study investigating the safety and tolerability of single and multiple ascending doses of nebulised SIS to healthy subjects. The randomized, double-blind trial was the first systematic, placebo-controlled study investigating the safety and tolerability of inhaled HOCl in humans. A total of 57 healthy volunteers were randomised to receive SIS formulations of up to 100 µg/ml HOCl, four times daily for five days, or a matching placebo regimen.

“SIS has the potential to be a breakthrough in respiratory treatment”, stated CEO Geir Almås of SoftOx, “the broad spectrum antimicrobial effect of SIS obviates the need for expensive diagnostic testing which can also delay the start of treatment, and would represent a paradigm shift in the management of respiratory infections.”

Data from the study demonstrates that an aqueous formulation of HOCl can be administered to the respiratory tract as an aerosol, as evidenced by dose-response effects on safety parameters, which were predominantly mild, even in the most intensive dosing regimen.

With these positive results from the Phase 1 study, SoftOx will continue Phase 2 clinical development of SIS. The company is already in the process of preparing Phase 2 documentation and is engaged in dialogue with the European Medical Association.

For more information about the SIS-01 study, please visit clinicaltrials.gov and reference identifier: NCT05188638.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Christopher Burton, CMO, SIS, SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

The information included in this announcement is defined as inside information pursuant to MAR article 7 and is publicly disclosed in accordance with MAR article 17. The announcement is made by the IR responsible.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
pharmaceutical/medtech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com

Kilde

[Mrodseth]

Ja💪…
HOCl can be administered to the respiratory tract as an aerosol, as evidenced by dose-response effects on safety parameters, which were predominantly mild, even in the most intensive dosing regimen.

[Oppsann]

Ante meg at det resultatene ville komme tidligere ja, selskapet guidet 1 måned til meg, men sikret seg og skrev ut q2. Deilig

[hummels]

BOOM!!! Kjøh

[XCR]

Fortsetter å levere!!

[XCR]

Denne er fin å ta med seg til Paris!

[rockybalboa]

Sten på sten. Full tillit!

[pips]

Knallgod melding. Første hinder for SIS er tilbakelagt.
Markedet er som vanlig ikke med for fem flate øre. Dette er stort.
Jeg er usikker på hvor viktig dette er for SDS og EDF det at vi nå har fått dette gjennom fase 1, men som utviklingscase i EDF må jo dette stå mye sterkere i en søknadsprosess.

Denne meldingen åpner mange nye dører, og det er merkelig at den høster så liten interesse.
Neste skritt nå er partneravtale med SIS. Skal Softox kunne starte med Fase 2 ila dette året, kan ikke den avtalen vente for lenge på seg.